E
ONCT

Ergoteles’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Ergoteles’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-621
Closed -$12.4K – 1917
2022
Q4 		$12.4K Sell
621
-4,409
-88% -$87.8K ﹤0.01% 1365
2022
Q3 		$90K Sell
5,030
-5,629
-53% -$121K ﹤0.01% 1397
2022
Q2 		$237K Buy
+10,659
New +$238K 0.01% 1233

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Ergoteles's ONCT Position: Q1 2023 in Review

Ergoteles sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2023, closing a stake of 621 shares — an estimated $12.4K sold.

Ergoteles first reported a position in ONCT in Q2 2022 and held it in 3 quarters. The position peaked at $237K in Q2 2022. 54 funds tracked by Wall St. Rank hold ONCT as of Q1 2023.

  • Ergoteles reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 621 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $12.4K.
  • Ergoteles first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Oncternal Therapeutics, Inc. Common Stock position peaked at $237K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.